180 related articles for article (PubMed ID: 11422019)
1. Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers.
Khaliq Y; Gallicano K; Tisdale C; Carignan G; Cooper C; McCarthy A
Br J Clin Pharmacol; 2001 Jun; 51(6):591-600. PubMed ID: 11422019
[TBL] [Abstract][Full Text] [Related]
2. Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers.
Ridtitid W; Wongnawa M; Mahatthanatrakul W; Chaipol P; Sunbhanich M
J Pharm Pharmacol; 2000 Oct; 52(10):1265-9. PubMed ID: 11092571
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir.
Gutierrez MM; Rosenberg J; Abramowitz W
Clin Ther; 2003 Apr; 25(4):1200-10. PubMed ID: 12809966
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults.
Rattanapunya S; Cressey TR; Rueangweerayut R; Tawon Y; Kongjam P; Na-Bangchang K
Malar J; 2015 Oct; 14():400. PubMed ID: 26452725
[TBL] [Abstract][Full Text] [Related]
5. Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers.
Ridtitid W; Wongnawa M; Mahatthanatrakul W; Raungsri N; Sunbhanich M
J Clin Pharm Ther; 2005 Jun; 30(3):285-90. PubMed ID: 15896247
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interaction trial between co-artemether and mefloquine.
Lefèvre G; Bindschedler M; Ezzet F; Schaeffer N; Meyer I; Thomsen MS
Eur J Pharm Sci; 2000 Apr; 10(2):141-51. PubMed ID: 10727880
[TBL] [Abstract][Full Text] [Related]
7. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure.
Mathias AA; West S; Hui J; Kearney BP
Clin Pharmacol Ther; 2009 Jan; 85(1):64-70. PubMed ID: 18815591
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
Kakuda TN; DeMasi R; van Delft Y; Mohammed P
HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir.
Muirhead GJ; Wulff MB; Fielding A; Kleinermans D; Buss N
Br J Clin Pharmacol; 2000 Aug; 50(2):99-107. PubMed ID: 10930961
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers.
Peytavin G; Gautran C; Otoul C; Cremieux AC; Moulaert B; Delatour F; Melac M; Strolin-Benedetti M; Farinotti R
Eur J Clin Pharmacol; 2005 Jun; 61(4):267-73. PubMed ID: 15889300
[TBL] [Abstract][Full Text] [Related]
11. Food increases the bioavailability of mefloquine.
Crevoisier C; Handschin J; Barré J; Roumenov D; Kleinbloesem C
Eur J Clin Pharmacol; 1997; 53(2):135-9. PubMed ID: 9403285
[TBL] [Abstract][Full Text] [Related]
12. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.
Aarnoutse RE; Grintjes KJ; Telgt DS; Stek M; Hugen PW; Reiss P; Koopmans PP; Hekster YA; Burger DM
Clin Pharmacol Ther; 2002 Jan; 71(1):57-67. PubMed ID: 11823758
[TBL] [Abstract][Full Text] [Related]
13. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food.
Kakuda TN; Sekar V; Lavreys L; De Paepe E; Stevens T; Vanstockem M; Vangeneugden T; Hoetelmans RM
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):346-52. PubMed ID: 27129006
[TBL] [Abstract][Full Text] [Related]
15. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
Freise KJ; Hu B; Salem AH
Eur J Clin Pharmacol; 2018 Apr; 74(4):413-421. PubMed ID: 29302721
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.
Hsu A; Granneman GR; Cao G; Carothers L; Japour A; El-Shourbagy T; Dennis S; Berg J; Erdman K; Leonard JM; Sun E
Antimicrob Agents Chemother; 1998 Nov; 42(11):2784-91. PubMed ID: 9797204
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Le Tiec C; Barrail A; Goujard C; Taburet AM
Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
[TBL] [Abstract][Full Text] [Related]
18. Drug-drug interaction analysis of pyronaridine/artesunate and ritonavir in healthy volunteers.
Morris CA; Lopez-Lazaro L; Jung D; Methaneethorn J; Duparc S; Borghini-Fuhrer I; Pokorny R; Shin CS; Fleckenstein L
Am J Trop Med Hyg; 2012 Mar; 86(3):489-495. PubMed ID: 22403324
[TBL] [Abstract][Full Text] [Related]
19. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.
Ouellet D; Hsu A; Qian J; Locke CS; Eason CJ; Cavanaugh JH; Leonard JM; Granneman GR
Br J Clin Pharmacol; 1998 Aug; 46(2):111-6. PubMed ID: 9723818
[TBL] [Abstract][Full Text] [Related]
20. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
